Transcatheter closure of post-infarction ventricular septal defect with the Amplatzer Septal Occluder device.
There is an 80-90% mortality rate within the first 2 months of the occurrence of a post-infarction ventricular septal defect (VSD) with medical treatment alone. The muscular VSD presents a technical problem for the surgeon. Surgical treatment was unsuccessful in two patients. They were treated successfully using the Amplatzer Septal Occluder, with improvement in their condition.
Pesonen
E
E
Department of Pediatrics, Lund University Hospital, Sweden.
Thilen
U
U
Sandström
S
S
Arheden
H
H
Koul
B
B
Olsson
S E
SE
Wilson
R F
RF
Toher
C
C
Bank
A
A
Bass
J
J
D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D001241:Aspirin; D006328:Cardiac Catheterization / Q000295:instrumentation* / Q000379:methods; D005500:Follow-Up Studies; D006345:Heart Septal Defects, Ventricular / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D019919:Prosthesis Implantation / Q000295:instrumentation / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage; D016896:Treatment Outcome
D010959:Tissue Plasminogen Activator; D001241:Aspirin